{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:37:44Z","timestamp":1792575464136,"version":"4.5.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Systemic glucocorticoid immunosuppression (gsISP) is commonly used among patients receiving immune checkpoint inhibitor (ICI) therapy, but the associations of gsISP timing, dose, and duration with overall survival (OS) remain incompletely characterized.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine the associations of gsISP timing, dose, and duration with OS among ICI recipients.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study included ICI recipients treated at Massachusetts General Hospital, Brigham and Women\u2019s Hospital, and Dana-Farber Cancer Institute (MGBD) from May 31, 2015, through October 11, 2021, and matched ICI recipients from the TriNetX database from April 30, 2010, through October 11, 2021, for independent validation. The TriNetX cohort was matched 2:1 to the MGBD cohort using propensity scores based on patient baseline characteristics and year of ICI initiation.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n gsISP, evaluated according to timing relative to ICI initiation, prednisone-equivalent dose, and duration of exposure.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The main outcome was OS. Multivariable accelerated failure time models were used to estimate time ratios (TRs) and 95% CIs, with TR values less than 1 indicating shorter survival.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n This study included 39\u202f258 patients, with 13\u202f086 in the MGBD cohort and 26\u202f172 in the TriNetX cohort. In the MGBD and TriNetX cohorts, 53.6% and 55.4% of patients were men, and 63.6% and 64.2% were younger than 70 years (mean [SD] age, 64.7 [13.0] years and 64.9 [12.6] years), respectively. In the MGBD cohort, patients who received gsISP within 1 year of ICI initiation had worse OS compared with patients not treated with gsISP, with the most pronounced association observed among patients receiving gsISP within 1 month of ICI initiation (TR, 0.49 [95% CI, 0.45-0.54]). Higher doses and longer durations were also associated with shorter OS; dosages greater than 60 mg\/d were associated with 37% (95% CI, 25%-52%) shorter OS, and durations longer than 7 days were associated with 33% (95% CI, 12%-49%) shorter OS. These findings were independently validated in the TriNetX cohort.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of ICI recipients, 3 factors were associated with worse OS: gsISP near ICI initiation, higher gsISP dose, and longer gsISP duration, regardless of indication. These findings may provide clinically relevant information to guide gsISP management among ICI recipients.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.14323","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T15:30:24Z","timestamp":1779463824000},"page":"e2614323","source":"Crossref","is-referenced-by-count":5,"title":["Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor Recipients"],"prefix":"10.1001","volume":"9","author":[{"given":"Guihong","family":"Wan","sequence":"first","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nga","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Khattab","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boshen","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munachimso","family":"Amadife","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie W.","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Rajeh","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Thang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Boland","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Hsing","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gusev","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"LeBoeuf","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Center for Cutaneous Oncology, Dana-Farber Brigham Cancer Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn G.","family":"Kwatra","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Maryland School of Medicine, Baltimore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgeniy R.","family":"Semenov","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"zoi260419r1","doi-asserted-by":"publisher","first-page":"11057","DOI":"10.1200\/JCO.2024.42.16_suppl.11057","article-title":"Overlapping and non-overlapping indications for checkpoint inhibitors in the US.","volume":"42","author":"Paul","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi260419r2","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jaccao.2022.09.004","article-title":"Immune checkpoint inhibitor therapy in oncology: current uses and future directions.","volume":"4","author":"Tan","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"5","key":"zoi260419r3","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.jaad.2022.12.048","article-title":"Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study.","volume":"88","author":"Zhang","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"zoi260419r4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.52302","article-title":"Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors.","volume":"7","author":"Cook","year":"2024","journal-title":"JAMA Netw Open"},{"key":"zoi260419r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors: a systematic review and meta-analysis.","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"zoi260419r6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"31","key":"zoi260419r7","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1200\/JCO.24.00191","article-title":"Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials.","volume":"42","author":"Verheijden","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi260419r8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/jitc-2020-002261","article-title":"Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer.","volume":"9","author":"Maslov","year":"2021","journal-title":"J Immunother Cancer"},{"key":"zoi260419r9","doi-asserted-by":"publisher","DOI":"10.1177\/1758835921996656","article-title":"Impact of the corticosteroid indication and administration route on overall survival and the tumor response after immune checkpoint inhibitor initiation.","author":"Gaucher","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"zoi260419r10","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study.","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"zoi260419r11","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ejca.2020.12.012","article-title":"Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors.","volume":"145","author":"Skribek","year":"2021","journal-title":"Eur J Cancer"},{"key":"zoi260419r12","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.3389\/fonc.2020.01677","article-title":"Immune-related adverse events and corticosteroid use for cancer-related symptoms are associated with efficacy in patients with non-small cell lung cancer receiving anti-PD-(L)1 blockade agents.","volume":"10","author":"Riudavets","year":"2020","journal-title":"Front Oncol"},{"issue":"22","key":"zoi260419r13","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications.","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"zoi260419r14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/cancers15113041","article-title":"Better late than never: the impact of steroidal treatment on the outcome of melanoma patients treated with immunotherapy.","volume":"15","author":"Bar-Hai","year":"2023","journal-title":"Cancers (Basel)"},{"key":"zoi260419r15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.928390","article-title":"The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy.","volume":"12","author":"Bruera","year":"2022","journal-title":"Front Oncol"},{"issue":"12","key":"zoi260419r16","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1002\/sim.3150","article-title":"A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003.","volume":"27","author":"Austin","year":"2008","journal-title":"Stat Med"},{"issue":"8","key":"zoi260419r17","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S1470-2045(24)00278-X","article-title":"Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study.","volume":"25","author":"Wan","year":"2024","journal-title":"Lancet Oncol"},{"issue":"2","key":"zoi260419r18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s12350-019-01624-z","article-title":"Landmark analysis: a primer.","volume":"26","author":"Morgan","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"zoi260419r19","doi-asserted-by":"publisher","first-page":"b5087","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes.","volume":"340","author":"L\u00e9vesque","year":"2010","journal-title":"BMJ"},{"issue":"1","key":"zoi260419r20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41416-024-02887-1","article-title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review.","volume":"132","author":"Jayathilaka","year":"2025","journal-title":"Br J Cancer"},{"issue":"4","key":"zoi260419r21","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/jcpt.13469","article-title":"Impact of corticosteroid use on outcomes of non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.","volume":"46","author":"Zhang","year":"2021","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"zoi260419r22","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/neuonc\/noab046","article-title":"The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis.","volume":"23","author":"Jessurun","year":"2021","journal-title":"Neuro Oncol"},{"issue":"5","key":"zoi260419r23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/cancers14051296","article-title":"Is timing of steroid exposure prior to immune checkpoint inhibitor initiation associated with treatment outcomes in melanoma? A population-based study.","volume":"14","author":"Nikita","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"10","key":"zoi260419r24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.40695","article-title":"Survival among veterans receiving steroids for immune-related adverse events after immune checkpoint inhibitor therapy.","volume":"6","author":"Van Buren","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi260419r25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy.","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"key":"zoi260419r26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fendo.2018.00235","article-title":"Regulatory and mechanistic actions of glucocorticoids on T and inflammatory cells.","volume":"9","author":"Liberman","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"zoi260419r27","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1001\/archinte.1984.00350170119021","article-title":"Prednisone and T-cell subpopulations.","volume":"144","author":"Schuyler","year":"1984","journal-title":"Arch Intern Med"},{"key":"zoi260419r28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12865-015-0103-2","article-title":"Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: an insight into the optimum application of glucocorticoids in anti-cancer therapy.","volume":"16","author":"Xing","year":"2015","journal-title":"BMC Immunol"},{"key":"zoi260419r29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40425-016-0177-2","article-title":"Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy.","volume":"4","author":"Agrawal","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"19","key":"zoi260419r30","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors.","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res"},{"key":"zoi260419r31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1508512","article-title":"Predictors of severity and onset timing of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a retrospective analysis.","volume":"16","author":"Fang","year":"2025","journal-title":"Front Immunol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2849282\/wan_2026_oi_260419_1778857503.4545.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T15:30:25Z","timestamp":1779463825000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2849282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.14323","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]}}}